DE60335647D1 - Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden - Google Patents
Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschädenInfo
- Publication number
- DE60335647D1 DE60335647D1 DE60335647T DE60335647T DE60335647D1 DE 60335647 D1 DE60335647 D1 DE 60335647D1 DE 60335647 T DE60335647 T DE 60335647T DE 60335647 T DE60335647 T DE 60335647T DE 60335647 D1 DE60335647 D1 DE 60335647D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- ischemia
- betablocker
- pyrroloquinoline quinone
- reperfusion damage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/146,566 US7276514B2 (en) | 2002-05-15 | 2002-05-15 | Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof |
PCT/US2003/015187 WO2003097056A1 (en) | 2002-05-15 | 2003-05-14 | Pyrroloquinoline quinone for treatment of cardiac injury and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60335647D1 true DE60335647D1 (de) | 2011-02-17 |
Family
ID=29418840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60335647T Expired - Lifetime DE60335647D1 (de) | 2002-05-15 | 2003-05-14 | Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden |
Country Status (8)
Country | Link |
---|---|
US (2) | US7276514B2 (de) |
EP (1) | EP1558256B1 (de) |
JP (1) | JP2005530786A (de) |
AT (1) | ATE493985T1 (de) |
AU (1) | AU2003237851A1 (de) |
CA (1) | CA2497601A1 (de) |
DE (1) | DE60335647D1 (de) |
WO (1) | WO2003097056A1 (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
US7276514B2 (en) | 2002-05-15 | 2007-10-02 | Charitable Leadership Foundation - Medical Technology Acceleration Program | Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof |
US20080051428A1 (en) * | 2002-05-15 | 2008-02-28 | Davis Paul J | Pyrroloquinoline quinone drugs and methods of use thereof |
WO2005107871A2 (en) * | 2004-05-05 | 2005-11-17 | Clf Medical Technology Acceleration Program, Inc. | Pyrroloquinoline quinone drugs for treatment of cardiac injury |
DE602005025755D1 (de) | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
US9139630B2 (en) | 2006-07-11 | 2015-09-22 | Rutgers, The State University Of New Jersey | Compositions and methods for preparing recombinant MG53 and methods for optimizing same |
US9458465B2 (en) * | 2007-12-04 | 2016-10-04 | Rutgers, The State University Of New Jersey | Compositions and methods to modulate cell membrane resealing |
JP5228912B2 (ja) * | 2006-09-08 | 2013-07-03 | 三菱瓦斯化学株式会社 | 高血圧改善剤 |
JP5672751B2 (ja) * | 2010-04-07 | 2015-02-18 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンを含むリポソーム |
US20130123340A1 (en) * | 2010-05-11 | 2013-05-16 | Peking University, Office Of Technology Transfer | Compositions and methods for the treatment and prevention of cardiac ischemic injury |
KR101496794B1 (ko) | 2010-11-05 | 2015-02-27 | 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 | 조직 손상에 대한 진단 마커로서의 혈청 mg53 |
WO2012157721A1 (ja) * | 2011-05-17 | 2012-11-22 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンと糖を含むリポソーム |
NO2722331T3 (de) | 2011-06-16 | 2018-02-03 | ||
US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
WO2017050171A1 (zh) * | 2015-09-25 | 2017-03-30 | 浙江海正药业股份有限公司 | 吡咯并喹啉醌钠盐的晶型及其制备方法和用途 |
US20190298684A1 (en) * | 2018-03-27 | 2019-10-03 | So Young Life Sciences Corporation | Compositions For Reducing Negative Effects Of Alcohol Consumption |
CN110870866A (zh) * | 2018-09-03 | 2020-03-10 | 浙江医药股份有限公司新昌制药厂 | 吡咯喹啉醌在制备用于防治急性高原反应和急性高原低氧损伤的药物中的应用 |
IT202000025603A1 (it) * | 2020-10-28 | 2022-04-28 | Longeva Health S R L | Composizione per prevenire e trattare lo scompenso e/o l’insufficienza cardiaca |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1302275C (en) * | 1986-08-07 | 1992-06-02 | Yuji Narutomi | Enzyme inhibitor |
SE8703881D0 (sv) * | 1987-10-08 | 1987-10-08 | Haessle Ab | New pharmaceutical preparation |
US5145862A (en) * | 1990-08-16 | 1992-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of resisting neurodegenerative disorders |
US5091391A (en) * | 1990-08-16 | 1992-02-25 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of resisting neurodegenerative disorders |
JP3218038B2 (ja) * | 1991-09-09 | 2001-10-15 | ワーナー−ランバート・コンパニー | 尿酸***促進剤およびeaa拮抗剤の組合せのための医薬組成物 |
AU3222893A (en) | 1991-11-25 | 1993-06-28 | University Of Michigan, The | Therapeutic composition and method for preventing reperfusion injury |
US5460819A (en) | 1991-12-13 | 1995-10-24 | Children's Medical Center Corporation | Method for treating PQQ-responsive heavy metal toxicity |
US5616576A (en) * | 1994-07-12 | 1997-04-01 | The Children's Medical Center Corporation | Controlling bone resorption with pyrroloquinoline quinone (PQQ) and related compounds |
JP4777489B2 (ja) | 1997-03-31 | 2011-09-21 | ザ チルドレンズ メディカル センター コーポレーション | アポトーシス性酵素を不活性化するためのニトロシル化 |
WO2004010924A2 (en) * | 2002-04-04 | 2004-02-05 | Children's Medical Center Corporation | Pyrroloquinoline quinone drugs as a neuroprotectant and methods of use thereof |
US7276514B2 (en) * | 2002-05-15 | 2007-10-02 | Charitable Leadership Foundation - Medical Technology Acceleration Program | Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof |
-
2002
- 2002-05-15 US US10/146,566 patent/US7276514B2/en not_active Expired - Fee Related
-
2003
- 2003-05-14 JP JP2004505055A patent/JP2005530786A/ja active Pending
- 2003-05-14 CA CA002497601A patent/CA2497601A1/en not_active Abandoned
- 2003-05-14 AU AU2003237851A patent/AU2003237851A1/en not_active Abandoned
- 2003-05-14 DE DE60335647T patent/DE60335647D1/de not_active Expired - Lifetime
- 2003-05-14 AT AT03736611T patent/ATE493985T1/de not_active IP Right Cessation
- 2003-05-14 EP EP03736611A patent/EP1558256B1/de not_active Expired - Lifetime
- 2003-05-14 WO PCT/US2003/015187 patent/WO2003097056A1/en active Search and Examination
-
2007
- 2007-10-02 US US11/906,769 patent/US20080221145A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2005530786A (ja) | 2005-10-13 |
AU2003237851A1 (en) | 2003-12-02 |
EP1558256B1 (de) | 2011-01-05 |
ATE493985T1 (de) | 2011-01-15 |
US20080221145A1 (en) | 2008-09-11 |
US20030216424A1 (en) | 2003-11-20 |
WO2003097056A1 (en) | 2003-11-27 |
US7276514B2 (en) | 2007-10-02 |
CA2497601A1 (en) | 2003-11-27 |
EP1558256A1 (de) | 2005-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60335647D1 (de) | Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden | |
DK1539166T3 (da) | Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme | |
ATE419859T1 (de) | Verwendung von probiotischen bakterien zur herstellung von topischen zusammensetzungen zum schutz der haut | |
MX2007007781A (es) | Composiciones cardiovasculares. | |
TW200612905A (en) | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | |
TW200611702A (en) | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | |
ATE296094T1 (de) | Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen | |
MX2007005723A (es) | Articulos para tratamiento que pueden amoldarse a una forma subyacente. | |
ATE499098T1 (de) | Verwendung von parp-1-hemmern | |
ATE473728T1 (de) | Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare | |
DE602005016198D1 (de) | Verwendung von Hülsenfrüchten zur Herstellung von Produkten zum Schutz oder Behandlung von radiotherapie-bedingten Hautschäden | |
NO20052153L (no) | Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer. | |
CY1108042T1 (el) | Θεραπεια εντερικων καταστασεων με ν-2,3,3-τετραμεθυλδικυκλο[2.2.1]επταν-2-αμινη | |
WO2007130509A3 (en) | Pyrroloquinoline quinones and use thereof | |
DE602005016729D1 (de) | Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung | |
ATE516040T1 (de) | Zusammensetzung und verwendung zur vorbeugung oder behandlung von stomatitis | |
ATE420089T1 (de) | Substituierte azachinazoline mit antiviraler wirkung | |
CY1107562T1 (el) | Χρηση των ν-(2-αρυλ-προπιονυλ)-σουκλφοναμιδιων για τη θepαπεια του τραυματος του νωτιαιου μυελου | |
ATE448779T1 (de) | Methode zur behandlung trockener augen und uveitis | |
NO20060420L (no) | 2-aminobenzoylderivater | |
DE60313803D1 (de) | Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen | |
WO2005107871A3 (en) | Pyrroloquinoline quinone drugs for treatment of cardiac injury | |
ATE406171T1 (de) | Aplidine zur behandlung von multiplem myelom | |
DE60142786D1 (de) | Zusammensetzungen und methoden zur behandlung von candidosen | |
EA200601392A1 (ru) | Способы и композиции для лечения липодистрофии |